VERO BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing next-generation cancer therapies, provides updates ...

HANOVER, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of ...

VERO BEACH, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today provided ...

ORLANDO, FL / ACCESS Newswire / December 26, 2025 / RedChip Companies will air interviews with Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) on the ...

Processa Pharmaceuticals Inc. company and executive profile by Barron's. View the latest PCSA company infomation and executive bios.

The average one-year price target for Processa Pharmaceuticals (NasdaqCM:PCSA) has been revised to $25.50 / share. This is an increase of 2,400.00% from the prior estimate of $1.02 dated December 3, ...

ORLANDO, FLORIDA / ACCESS Newswire / July 18, 2025 / RedChip Companies will air interviews with Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) and BullFrog AI, Inc. (Nasdaq:BFRG) on the RedChip Small ...

VERO BEACH, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today ...

David Young, PharmD, PhD, Founder and President, Research and Development, of Processa Pharmaceuticals, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the Company’s ...

David Young, PharmD, PhD, Founder and President, Research and Development, of Processa Pharmaceuticals, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the Company's ...